Concerted changes in the pediatric single-cell intestinal ecosystem before and after anti-TNF blockade

Access Granted
Updated January 6, 2025

Crohn’s disease is an inflammatory bowel disease (IBD) commonly treated through anti-TNF blockade. However, most patients still relapse and inevitably progress. Comprehensive single-cell RNA-sequencing (scRNA-seq) atlases have largely sampled patients with established treatment-refractory IBD, limiting our understanding of which cell types, subsets, and states at diagnosis anticipate disease severity and response to treatment. Here, through combining clinical, flow cytometry, histology, and scRNA-seq methods, we profile diagnostic human biopsies from the terminal ileum of treatment-naïve pediatric patients with Crohn’s disease (pediCD; n=14), matched repeat biopsies (pediCD-treated; n=8) and from non-inflamed pediatric controls with functional gastrointestinal disorders (FGID; n=13). To resolve and annotate epithelial, stromal, and immune cell states among the 201,883 baseline single-cell transcriptomes, we develop a principled and unbiased tiered clustering approach, ARBOL. Through flow cytometry and scRNA-seq, we observe that treatment-naïve pediCD and FGID have similar broad cell type composition. However, through high-resolution scRNA-seq analysis and microscopy, we identify significant differences in cell subsets and states that arise during pediCD relative to FGID. By closely linking our scRNA-seq analysis with clinical meta-data, we resolve a vector of T cell, innate lymphocyte, myeloid, and epithelial cell states in treatment-naïve pediCD (pediCD-TIME) samples which can distinguish patients along the trajectory of disease severity and anti-TNF response. By using ARBOL with integration, we position repeat on-treatment biopsies from our patients between treatment-naïve pediCD and on-treatment adult CD. We identify that anti-TNF treatment pushes the pediatric cellular ecosystem towards an adult, more treatment-refractory state. Our study jointly leverages a treatment-naïve cohort, high-resolution principled scRNA-seq data analysis, and clinical outcomes to understand which baseline cell states may predict Crohn’s disease trajectory.

Alex K ShalekMassachusetts Institute of Technology; Harvard Medical Schoolshalek@mit.edu
Jose Ordovas-MontanesBoston Children’s Hospital; Massachusetts Institute of Technology; Harvard Medical School; Harvard Stem Cell Institutejose.ordovas-montanes@childrens.harvard.edu
Leslie S KeanBoston Children’s Hospital; Dana Farber Cancer InstituteLeslie_Kean@dfci.harvard.edu
Hengqi Betty Zheng1
Benjamin A Doran2
Kyle Kimler2
Alison Yu3
Victor Tkachev3
Veronika Niederlova4
Kayla Cribbin3
Ryan Fleming3
Brandi Bratrude3
Kayla Betz3
Lorenzo Cagnin3
Connor McGuckin3
Paula Keskula3
Alexandre Albanese3
Maria Sacta3
Joshua de Sousa Casal5
Ruben van Esch6
Andrew C Kwong7
Conner Kummerlowe8
Faith Taliaferro2
Nathalie Fiaschi9
Baijun Kou9
Sandra Coetzee9
Sumreen Jalal9
Yoko Yabe9
Michael Dobosz9
Matthew F Wipperman9
Sara Hamon9
George D Kalliolias9
Andrea Hooper9
Wei Keat Lim9
Sokol Haxhinasto9
Yi Wei9
Madeline Ford1
Lusine Ambartsumyan1
David L Suskind1
Dale Lee1
Gail Deutsch1
Xuemei Deng1
Lauren V Collen3
Vanessa Mitsialis10
Scott B Snapper11
Ghassan Wahbeh1
Alex K Shalek12
Jose Ordovas-Montanes13
Leslie S Kean14
1Seattle Children’s Hospital and University of Washington
2Boston Children’s Hospital;Massachusetts Institute of Technology
3Boston Children’s Hospital
4Boston Children’s Hospital; Massachusetts Institute of Technology; Institute of Molecular Genetics of the Czech Academy of Sciences
5Boston Children’s Hospital; Harvard Medical School
6UMC Utrecht
7Boston Children’s Hospital; Broad Institute of MIT and Harvard
8Massachusetts Institute of Technology; Broad Institute of MIT and Harvard
9Regeneron Pharmaceuticals Inc.
10Boston Children’s Hospital; Brigham and Women’s Hospital Department of Medicine
11Boston Children’s Hospital; Brigham and Women’s Hospital Department of Medicine; Harvard Medical School
12Massachusetts Institute of Technology; Harvard Medical School
13Boston Children’s Hospital; Massachusetts Institute of Technology; Harvard Medical School; Harvard Stem Cell Institute
14Boston Children’s Hospital; Dana Farber Cancer Institute
Arsenios Chatzigeorgiou

To reference this project, please use the following link:

https://explore.data.humancellatlas.org/projects/474a4229-840e-4d63-82af-8d3aa615ee17

Supplementary links are provided by contributors and represent items such as additional data which can’t be hosted here; code that was used to analyze this data; or tools and visualizations associated with this specific dataset.

1.https://singlecell.broadinstitute.org/single_cell/study/SCP1422/predict-2021-paper-fgid2.https://singlecell.broadinstitute.org/single_cell/study/SCP1423/predict-2021-paper-cd
None

Atlas

GutGut v1.0

Analysis Portals

None

Project Label

PediatricIntestineTNFZheng10x

Species

Homo sapiens

Sample Type

specimens

Anatomical Entity

Small intestine

Organ Part

ileal mucosa

Selected Cell Types

Unspecified

Disease Status (Specimen)

2 disease statuses

Disease Status (Donor)

2 disease statuses

Development Stage

3 development stages

Library Construction Method

10x 3' v2

Nucleic Acid Source

single cell

Paired End

false

Analysis Protocol

cellranger_protocol

File Format

4 file formats

Cell Count Estimate

201.9k

Donor Count

27
csv4 file(s)mtx2 file(s)tsv4 file(s)xlsx1 file(s)
HCA Data PortalHCA Data Portal
AboutHelpPrivacyContact
v3.3.0-6152ec5-dcp59